Contents

VISUAL II: Adalimumab in Patients with Active Noninfectious Uveitis


Main finding: Adalimumab significantly decreased the risk of uveitic flare or loss of visual acuity upon corticosteroid withdrawal in patients with inactive, non-infectious intermediate, posterior, or panuveitic uveitis on systemic corticosteroids.

 

Study characteristics:

 

  • Name: VISUAL II study
  • Purpose: To assess the efficacy and safety of adalimumab in preventing reactivation of uveitis
  • Type: Randomised controlled Trial
  • Condition: Non-infectious intermediate, posterior, and panuveitic uveitis controlled by corticosteroids.
  • Year results published: 2016

Participants: ≥18 years, inactive non-infectious intermediate, posterior or panuveitic uveitis. At least one disease flare within 18 months of screening visit. On oral prednisone 10-35mg/day to maintain inactivity.

 

  • n=229

 

Intervention:

 

Group 1: Placebo
Group 2: Adalimumab (80mg loading dose then 40mg every 2 weeks)

 

Both groups were on Prednisone 10-35mg/day at baseline and were tapered off to 0mg by week 19.

Treatment failure occurred in 55% of patients in the placebo group vs 39% in the adalimumab group.

 

Time to treatment failure was significantly improved in the adalimumab group compared with the placebo group (>18 monthsvs 8·3 months)

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed